Last update 01 Nov 2024

CACNG1

Last update 01 Nov 2024

Basic Info

Synonyms

CACNG1, CACNLG, calcium channel, voltage-dependent, gamma subunit 1

+ [3]

Introduction

Regulatory subunit of the voltage-gated calcium channel that gives rise to L-type calcium currents in skeletal muscle. Regulates channel inactivation kinetics.

Drugs associated with CACNG1

Anti-CACNG1 antibody DMPK siRNA conjugates(Regeneron)

Target

CACNG1 x DMPK

Mechanism

CACNG1 blockers [+1]

Active Org.

Regeneron Pharmaceuticals, Inc.

Originator Org.

Regeneron Pharmaceuticals, Inc.

Active Indication

Musculoskeletal Diseases

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

WO2024098002

Patent Mining

Target

CACNG1

Mechanism-

Active Org.

Regeneron Pharmaceuticals, Inc.

Originator Org.

Regeneron Pharmaceuticals, Inc.

Active Indication

Congenital Disorders [+1]

Inactive Indication-

Drug Highest PhaseDiscovery

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Diltiazem Malate

Target

CACNG1

Mechanism

CACNG1 blockers

Active Org.-

Originator Org.

Merck & Co., Inc.

Active Indication-

Inactive Indication

Angina Pectoris [+5]

Drug Highest PhaseWithdrawn

First Approval Ctry. / Loc.

First Approval Date04 Oct 1996

Clinical Trials associated with CACNG1

NCT06534671 / Enrolling by invitationPhase 4IIT

Diltiazem in Jervell and Lange-Nielsen Syndrome

This study will test the effect of diltiazem, a calcium channel blocking drug, on the QT interval in patients with Jervell and Lange-Nielsen syndrome. This will be a single IV dose and acute effects (within minutes) will be observed.

Start Date16 Oct 2024

Sponsor / Collaborator

Vanderbilt University Medical Center

IRCT20210519051345N53 / RecruitingIIT

Fasted-state in vivo bioequivalence study of Diltiazem 60 mg tablet manufactured by MehrDarou compared with innovator product

Start Date13 Apr 2024

Sponsor / Collaborator

Tabriz University of Medical Sciences

CTRI/2023/09/057330 / RecruitingPhase 4

Efficacy and safety of Murivenna anal infiltration compared to Diltiazem topical application in chronic anal fissure: A prospective randomized open-label clinical trial - CAF

Start Date07 Sep 2023

Sponsor / Collaborator

Central Council For Research In Ayurvedic Sciences

100 Clinical Results associated with CACNG1

100 Translational Medicine associated with CACNG1

0 Patents (Medical) associated with CACNG1

118

Literatures (Medical) associated with CACNG1

25 Jul 2023·Schizophrenia (Heidelberg, Germany)

Genome-wide association study identified six loci associated with adverse drug reactions to aripiprazole in schizophrenia patients.

Article

Author: Wang, Xueping ; Lu, Zhe ; Yue, Weihua ; Sun, Yaoyao ; Zhang, Yuyanan ; Lu, Tianlan ; Yan, Hao ; Mei, Dongli

Aripiprazole is recommended for routine use in schizophrenia patients. However, the biological mechanism for the adverse drug reactions (ADRs) among schizophrenia patients with the antipsychotic drug aripiprazole is far from clear. To explore the potential genetic factors that may cause movement-related adverse antipsychotic effects in patients, we conducted an association analysis between movement-related ADRs and SNPs in schizophrenia patients receiving aripiprazole monotherapy. In this study, multiple ADRs of 384 patients were quantified within 6-week treatment, and the scores of movement-related ADRs at baseline and follow-up time points during treatment were obtained. The highest score record was used as the quantitative index in analysis, and genetic analysis at the genome-wide level was conducted. The SNP rs4149181 in SLC22A8 [P = 2.28 × 10^-8] showed genome-wide significance, and rs2284223 in ADCYAP1R1 [P = 9.76 × 10^-8], rs73258503 in KCNIP4 [P = 1.39 × 10^-7], rs678428 in SMAD9 [P = 4.70 × 10^-7], rs6421034 in NAP1L4 [P = 6.80 × 10^-7], and rs1394796 in ERBB4 [P = 8.60 × 10^-7] were found to be significantly associated with movement-related ADRs. The combined prediction model of these six loci showed acceptable performance in predicting adverse events [area under the curve (AUC): 0.84]. Combined with the function and network of the above genes and other candidate loci (KCNA1, CACNG1, etc.), we hypothesize that SLC22A8 and KCNIP4-Kv channel perform their respective functions as transporter or channel and participate in the in vivo metabolism or effects of aripiprazole. The above results imply the important function of ion transporters and channels in movement-related adverse antipsychotic effects in aripiprazole monotherapy schizophrenia patients.

01 May 2022·Protein ScienceQ4 · BIOLOGY

Molecular interactions of STAC proteins with skeletal muscle dihydropyridine receptor and excitation‐contraction coupling

Q4 · BIOLOGY

Article

Author: Oakley, Aaron J. ; Sundararaj, Srinivasan ; Rowland, Emily ; Aditya, Shouvik ; Casarotto, Marco G. ; Dulhunty, Angela F. ; Shishmarev, Dmitry

AbstractExcitation‐contraction coupling (ECC) is the physiological process in which an electrical signal originating from the central nervous system is converted into muscle contraction. In skeletal muscle tissue, the key step in the molecular mechanism of ECC initiated by the muscle action potential is the cooperation between two Ca2+ channels, dihydropyridine receptor (DHPR; voltage‐dependent L‐type calcium channel) and ryanodine receptor 1 (RyR1). These two channels were originally postulated to communicate with each other via direct mechanical interactions; however, the molecular details of this cooperation have remained ambiguous. Recently, it has been proposed that one or more supporting proteins are in fact required for communication of DHPR with RyR1 during the ECC process. One such protein that is increasingly believed to play a role in this interaction is the SH3 and cysteine‐rich domain‐containing protein 3 (STAC3), which has been proposed to bind a cytosolic portion of the DHPR α1S subunit known as the II–III loop. In this work, we present direct evidence for an interaction between a small peptide sequence of the II–III loop and several residues within the SH3 domains of STAC3 as well as the neuronal isoform STAC2. Differences in this interaction between STAC3 and STAC2 suggest that STAC3 possesses distinct biophysical features that are potentially important for its physiological interactions with the II–III loop. Therefore, this work demonstrates an isoform‐specific interaction between STAC3 and the II–III loop of DHPR and provides novel insights into a putative molecular mechanism behind this association in the skeletal muscle ECC process.

03 Oct 2018·Cancer Biology & TherapyQ3 · MEDICINE

Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients

Q3 · MEDICINE

Article

Author: Moscetti, Luca ; Conte, Pier Franco ; Cascinu, Stefano ; Guaitoli, Giorgia ; Caggia, Federica ; Bettelli, Stefania ; Piacentini, Federico ; Manfredini, Samantha ; Toss, Angela ; Caprera, Cecilia ; Cortesi, Laura ; Maiorana, Antonino ; Kaleci, Shaniko ; Omarini, Claudia

BACKGROUNDHER2+ metastatic breast cancer (MBC) is a poor prognosis disease, unusually curable. To date, no predictive factors have been clearly correlated with long-term response to anti-HER2 agents.METHODS54 HER2+ MBC patients treated with HER2 targeted therapy as first line treatment were analysed: 40 with a time to progression longer than 3 years in Long Responders (LR) group and 14 with a progression disease within one year of anti-HER2 therapy in a control group named Early Progressors (EP). The expression of 770 genes and 13 molecular pathways were evaluated using Nanostring PanCancer pathway panel performed on FFPE BC tissues.RESULTSConsidering baseline patients and tumor characteristics, EP women had more CNS spread and more metastatic burden of disease compared to LR (p > 0.05). Gene expression analysis identified 30 genes with significantly different expression in the two cohorts; five were driver genes (BRCA1, PDGFRA, AR, PHF6 and MSH2). The majority of these genes were over-expressed, mainly in LR patients, and encoded growth factors, pro- or anti-inflammatory interleukins and DNA repair factors. Only four genes were down regulated, all in EP group (TNFSF10, CACNG1, IL20RB and BRCA1). Most of these genes were involved in MAPK and PI3K pathways. MAPK pathway was differently expressed between LR and EP (p = 0.05). PI3K was the only pathway overexpressed in EP patients.CONCLUSIONSWhole genome expression analysis comparing LR vs. EP identified a group of genes that may predict more favourable long-term outcomes. Up-regulation of MAPK and down-regulation of PI3K pathway could be a positive predictive factors. Further clinical implications are warranted.ABBREVIATIONSBC: breast cancer; MBC: metastatic breast cancer; LR: long responder; EP: early progressor; FFPE: formalin-fixed paraffin-embedded; CNS: central nervous system; PFS: progression free survival; OS: overall survival.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

CACNG1

Basic Info

Related

Analysis